Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors

Challenges in comparative effectiveness using medicare data

S. Setoguchi, W. H. Shrank, J. Liu, Joy Lee, U. Saya, W. C. Winkelmayer, N. A. Dreyer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

An evidence gap exists in comparing the effectiveness of angiotensin receptor II blockers (ARBs) for hypertension with that of angiotensin-converting enzyme inhibitors (ACEIs). We identified elderly hypertensive patients in whom ACEI/ARB therapy had been initiated after hospitalization for coronary artery disease (CAD), heart failure (HF), or stroke and who were eligible for Medicare and state pharmacy assistance programs. Of 18,801 initiators of ACEIs and 2,641 initiators of ARBs, 2,535 died during the follow-up. We observed substantial differences in characteristics between ARB and ACEI initiators, suggesting that ARB users were more health seeking. The incidence of death and sudden cardiac death (SCD) in ACEI initiators was 77 and 22 per 1,000 person-years, respectively. The relative risk for SCD comparing ARB initiators to ACEI initiators was 0.69 (95% confidence interval (CI) 0.50-0.96); when the analysis was restricted to patients with low ejection fraction (EF), the relative risk was 1.1. The reduced risk of SCD can be explained, at least partly, by (i) residual confounding because ARB users were healthier on unobserved domains and (ii) lack of data on EF.

Original languageEnglish (US)
Pages (from-to)674-682
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume89
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Angiotensin Receptor Antagonists
Medicare
Angiotensin-Converting Enzyme Inhibitors
Sudden Cardiac Death
Coronary Artery Disease
Hospitalization
Heart Failure
Stroke
Confidence Intervals
Hypertension
Incidence
Health

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors : Challenges in comparative effectiveness using medicare data. / Setoguchi, S.; Shrank, W. H.; Liu, J.; Lee, Joy; Saya, U.; Winkelmayer, W. C.; Dreyer, N. A.

In: Clinical Pharmacology and Therapeutics, Vol. 89, No. 5, 01.05.2011, p. 674-682.

Research output: Contribution to journalArticle

Setoguchi, S. ; Shrank, W. H. ; Liu, J. ; Lee, Joy ; Saya, U. ; Winkelmayer, W. C. ; Dreyer, N. A. / Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors : Challenges in comparative effectiveness using medicare data. In: Clinical Pharmacology and Therapeutics. 2011 ; Vol. 89, No. 5. pp. 674-682.
@article{3da74175bbde4385a7812117d9a8e32a,
title = "Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: Challenges in comparative effectiveness using medicare data",
abstract = "An evidence gap exists in comparing the effectiveness of angiotensin receptor II blockers (ARBs) for hypertension with that of angiotensin-converting enzyme inhibitors (ACEIs). We identified elderly hypertensive patients in whom ACEI/ARB therapy had been initiated after hospitalization for coronary artery disease (CAD), heart failure (HF), or stroke and who were eligible for Medicare and state pharmacy assistance programs. Of 18,801 initiators of ACEIs and 2,641 initiators of ARBs, 2,535 died during the follow-up. We observed substantial differences in characteristics between ARB and ACEI initiators, suggesting that ARB users were more health seeking. The incidence of death and sudden cardiac death (SCD) in ACEI initiators was 77 and 22 per 1,000 person-years, respectively. The relative risk for SCD comparing ARB initiators to ACEI initiators was 0.69 (95{\%} confidence interval (CI) 0.50-0.96); when the analysis was restricted to patients with low ejection fraction (EF), the relative risk was 1.1. The reduced risk of SCD can be explained, at least partly, by (i) residual confounding because ARB users were healthier on unobserved domains and (ii) lack of data on EF.",
author = "S. Setoguchi and Shrank, {W. H.} and J. Liu and Joy Lee and U. Saya and Winkelmayer, {W. C.} and Dreyer, {N. A.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1038/clpt.2011.17",
language = "English (US)",
volume = "89",
pages = "674--682",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors

T2 - Challenges in comparative effectiveness using medicare data

AU - Setoguchi, S.

AU - Shrank, W. H.

AU - Liu, J.

AU - Lee, Joy

AU - Saya, U.

AU - Winkelmayer, W. C.

AU - Dreyer, N. A.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - An evidence gap exists in comparing the effectiveness of angiotensin receptor II blockers (ARBs) for hypertension with that of angiotensin-converting enzyme inhibitors (ACEIs). We identified elderly hypertensive patients in whom ACEI/ARB therapy had been initiated after hospitalization for coronary artery disease (CAD), heart failure (HF), or stroke and who were eligible for Medicare and state pharmacy assistance programs. Of 18,801 initiators of ACEIs and 2,641 initiators of ARBs, 2,535 died during the follow-up. We observed substantial differences in characteristics between ARB and ACEI initiators, suggesting that ARB users were more health seeking. The incidence of death and sudden cardiac death (SCD) in ACEI initiators was 77 and 22 per 1,000 person-years, respectively. The relative risk for SCD comparing ARB initiators to ACEI initiators was 0.69 (95% confidence interval (CI) 0.50-0.96); when the analysis was restricted to patients with low ejection fraction (EF), the relative risk was 1.1. The reduced risk of SCD can be explained, at least partly, by (i) residual confounding because ARB users were healthier on unobserved domains and (ii) lack of data on EF.

AB - An evidence gap exists in comparing the effectiveness of angiotensin receptor II blockers (ARBs) for hypertension with that of angiotensin-converting enzyme inhibitors (ACEIs). We identified elderly hypertensive patients in whom ACEI/ARB therapy had been initiated after hospitalization for coronary artery disease (CAD), heart failure (HF), or stroke and who were eligible for Medicare and state pharmacy assistance programs. Of 18,801 initiators of ACEIs and 2,641 initiators of ARBs, 2,535 died during the follow-up. We observed substantial differences in characteristics between ARB and ACEI initiators, suggesting that ARB users were more health seeking. The incidence of death and sudden cardiac death (SCD) in ACEI initiators was 77 and 22 per 1,000 person-years, respectively. The relative risk for SCD comparing ARB initiators to ACEI initiators was 0.69 (95% confidence interval (CI) 0.50-0.96); when the analysis was restricted to patients with low ejection fraction (EF), the relative risk was 1.1. The reduced risk of SCD can be explained, at least partly, by (i) residual confounding because ARB users were healthier on unobserved domains and (ii) lack of data on EF.

UR - http://www.scopus.com/inward/record.url?scp=79955477173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955477173&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.17

DO - 10.1038/clpt.2011.17

M3 - Article

VL - 89

SP - 674

EP - 682

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -